| Literature DB >> 20346187 |
Nilimesh Halder1, Joel K Kelso, George J Milne.
Abstract
BACKGROUND: Following the emergence of the A/H1N1 2009 influenza pandemic, public health interventions were activated to lessen its potential impact. Computer modelling and simulation can be used to determine the potential effectiveness of the social distancing and antiviral drug therapy interventions that were used at the early stages of the pandemic, providing guidance to public health policy makers as to intervention strategies in future pandemics involving a highly pathogenic influenza strain.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20346187 PMCID: PMC2853510 DOI: 10.1186/1471-2458-10-168
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Figure 1Dynamics of influenza progression within host individuals. (a) Dynamics of influenza A/H1N12009 progression within host individuals. (b) Infectivity curve of an infectious individual due to influenza infection.
Detailed description of each component of the transmission function
| Component of transmission function | Description |
|---|---|
| Probability of disease transmission from | |
| Disease transmission coefficient, chosen to achieve baseline epidemics with specific R0 values. | |
| Age specific susceptibility of | |
| Infectiousness of | |
| Antiviral factor which reduces transmission probability when antiviral based interventions are applied to individuals | |
| The following different situations may arise when we model antiviral effectiveness. | |
| if the infected individual is treated with antiviral drugs and no antiviral prophylaxis is applied to the susceptible individual | |
| if antiviral prophylaxis are applied to the susceptible individual and no antiviral treatment is used with the infected individual | |
| if both infected and susceptible individuals are receiving antiviral drugs for treatment and prophylaxis respectively | |
| if neither infector nor susceptible individuals are receiving antiviral drugs | |
Simulated characteristics of baseline (no-intervention) epidemics for R0 values
| R0 | ||||||
|---|---|---|---|---|---|---|
| 1.4 | 1.5 | 1.6 | ||||
| Characteristics | Mean | Mean | Mean | |||
| Final Infection Rate (%) | 36.3 | 1.32 | 43.9 | 1.09 | 50.4 | 1.02 |
| Final Attack Rate (%) | 26.9 | 0.95 | 32.5 | 0.77 | 37.2 | 0.74 |
| Peak Symptomatic Population (%) | 4.45 | 0.49 | 6.6 | 0.46 | 8.74 | 0.51 |
| Peak Daily incidence Rate (per 10000) | 82 | 8 | 121 | 9 | 159 | 10 |
| Peak Attack Day | 51 | 7.7 | 45 | 4.74 | 40 | 4.48 |
| Serial Interval | 2.49 | 0.01 | 2.47 | 0.01 | 2.45 | 0.01 |
Means and standard deviations (S.D.) are for 40 simulation runs, each with stochastic choices made with different random-number sequences.
Figure 2Epidemic progression curve expressed as daily incidence rate and cumulative illness rate. Top pair shows comparison among different school closure strategies with 1 week closing period. Central pair indicates the potential impact of antiviral drug usage during simulated pandemic period. Bottom pair illustrates the combined effectiveness of individual school closure for 1 week and antiviral strategies during pandemic. Results are illustrated in terms of daily incidence rate (symptomatic cases per day, left column) and cumulative symptomatic attack rate (percentage of population, right column).
Figure 3Final attack rate of epidemics with concurrent school closure and antiviral based strategies. Final attack rate (% of population) is presented for an epidemic with R0 = 1.5 and different antiviral based strategies in conjunction with individual school closure for variable school closure durations (0 week to 4 weeks).
Figure 4Peak daily incidence rate of epidemic with concurrent school closure and antiviral based strategies. The figure illustrates the impact of different durations of school closure coupled with antiviral based strategies on peak daily incidence rate during an epidemic. Peak daily incidence rate is expressed in symptomatic cases per 10000 population.
Figure 5Required antiviral courses (% of population) for an epidemic with R. The figure illustrates the consumption of antiviral drugs for different antiviral strategies combined with school closures during a pandemic.
Simulated outcomes for epidemics with different interventions
| R0 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1.4 | 1.5 | 1.6 | |||||||
| Intervention Policies | |||||||||
| No intervention | 27.9 | 82 | 0 | 32.5 | 121 | 0 | 37.2 | 159 | 0 |
| ISC | 23.5 | 53 | 0 | 29.3 | 74 | 0 | 34.1 | 100 | 0 |
| T | 21.1 | 54 | 10.4 | 26.6 | 84 | 13.3 | 32.2 | 120 | 16.0 |
| T+H | 12.6 | 24 | 18.4 | 18.7 | 41 | 25.2 | 23.4 | 62 | 30.3 |
| T+H+E | 9.0 | 15 | 30.6 | 13.0 | 22 | 40.2 | 19.9 | 39 | 45.8 |
| T + ISC | 16.9 | 32 | 8.5 | 23.8 | 53 | 11.5 | 27.9 | 77 | 14.1 |
| T + H + ISC | 10.1 | 14 | 14.2 | 14.8 | 23 | 20.8 | 20.8 | 41 | 26.9 |
| T + H + E + ISC | 7.1 | 10 | 25.0 | 10.9 | 17 | 35.3 | 15.5 | 30 | 44.8 |
Simulated Final Attack Rate % (FAR), Peak Daily Incidence Rate per 10,000 population (PDIR) and Required Anti Viral courses % (RAV) for epidemics with different interventions. Interventions abbreviations: T - antiviral treatment, H - household antiviral prophylaxis, E - extended prophylaxis, ISC - individual school closure (2 weeks duration, maximum of 2 closures per school).